Table 1 Pretreatment patient characteristics
| Â | Â | All patients | Palliative Chemotherapy | No Chemotherapy | p value |
|---|---|---|---|---|---|
| Â | Â | n = 91 | n = 40 | n = 51 | Â |
Age (years) | Median (range) | 58 (25 - 82) | 55 (25 - 74) | 59 (34 - 82) | 0.03 |
Gender | Male | 67 (73.6%) | 31 (77.5%) | 36 (70.6%) | 0.46 |
ECOG PS | 0/1 | 54 (59.3%) | 32 (80.0%) | 22 (43.1%) | <0.01 |
| Â | 2/3 | 33 (36.3%) | 8 (20.0%) | 25 (49.0%) | Â |
| Â | NA | 4 (4.4%) | 0 (0.0%) | 4 (7.8%) | Â |
Primary cancer site | Duodenum | 71 (78.0%) | 28 (70.0%) | 43 (84.3%) | 0.10 |
| Â | Jejunoileum | 20 (22.0%) | 12 (30.0%) | 8 (15.7%) | Â |
Histology | WD/MD | 44 (48.4%) | 18 (45.0%) | 26 (51.0%) | 0.57 |
| Â | Undifferentiated | 38 (41.8%) | 19 (47.5%) | 19 (37.3%) | Â |
| Â | Undetermined | 9 (9.8%) | 3 (7.5%) | 6 (11.8%) | Â |
Status | Recurrent | 17 (18.7%) | 11 (27.5%) | 6 (11.8%) | 0.15 |
| Â | Locally advanced | 4 (4.4%) | 2 (5.0%) | 2 (3.9%) | Â |
| Â | Metastatic | 70 (76.9%) | 27 (67.5%) | 43 (84.3%) | Â |
Primary tumor | Resected | 29 (31.9%) | 19 (47.5%) | 10 (19.6%) | <0.01 |
| Â | Still present | 62 (68.1%) | 21 (52.5%) | 41 (80.4%) | Â |
Number of metastasis | 0 | 4 (4.4%) | 2 (5.0%) | 2 (3.9%) | 0.62 |
| Â | 1 | 50 (54.9%) | 24 (60.0%) | 26 (51.0%) | Â |
|  | ≥2 | 37 (40.7%) | 14 (35.0%) | 23 (45.1%) |  |
Liver metastasis | Yes | 39 (42.9%) | 14 (35.0%) | 25 (49.0%) | 0.18 |
Peritoneal metastasis | Yes | 42 (46.2%) | 19 (47.5%) | 23 (45.1%) | 0.82 |
IALN metastasis | Yes | 41 (45.1%) | 13 (32.5%) | 28 (54.9%) | 0.03 |
Lung metastasis | Yes | 6 (6.6%) | 2 (5.0%) | 4 (7.8%) | 0.59 |
Bone metastasis | Yes | 3 (3.3%) | 2 (5.0%) | 1 (2.0%) | 0.42 |
Treatment interval | 1989-1999 | 25 (27.5%) | 10 (25.0%) | 15 (29.4%) | 0.64 |
| Â | 2000-2009 | 66 (72.5%) | 30 (75.0%) | 36 (70.6%) | Â |